GSK Share: Strong H1, Weak Price – Down 16% but Still 68% Undervalued
GlaxoSmithKline, widely known as GSK, recently reported a robust first half of 2025, with strong performance in its specialty medicines division and a bold forecast upgrade. Yet, paradoxically, the GSK share price remains weak, down around 16% from its year-high, despite evidence pointing to deep undervaluation.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
